These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 20828919)

  • 21. Does preoperative nutritional status affect survival in renal cell carcinoma? The debate continues.
    Capitanio U; Montorsi F
    Eur Urol; 2011 Jun; 59(6):929-30. PubMed ID: 21444146
    [No Abstract]   [Full Text] [Related]  

  • 22. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.
    Bex A; Powles T
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):787-97. PubMed ID: 22716495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
    Leroy X; Edeline J; Rioux-Leclercq N
    Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
    Karam JA; Wood CG
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting cancer-control outcomes in patients with renal cell carcinoma.
    Karakiewicz PI; Hutterer GC
    Curr Opin Urol; 2007 Sep; 17(5):295-302. PubMed ID: 17762620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Molecular targeted therapy for advanced renal cell carcinoma].
    Kanayama H
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
    Doehn Ch; Richter A; Lehmacher W; Jocham D
    Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multimodality treatment of metastatic renal cell carcinoma.
    Mickisch GH
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):681-5. PubMed ID: 12503214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presurgical therapy in metastatic renal cell carcinoma.
    Jonasch E
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):73-8. PubMed ID: 17187521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial comment.
    Singer EA; Srinivasan R; Bratslavsky G
    J Urol; 2011 Jan; 185(1):66. PubMed ID: 21074200
    [No Abstract]   [Full Text] [Related]  

  • 32. Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives.
    Timsit MO; Albiges L; Méjean A; Escudier B
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1559-69. PubMed ID: 23253222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving outcomes in patients with advanced renal cell carcinoma.
    Sosman JA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Harshman LC; Srinivas S
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Healy KA; Marshall FF; Ogan K
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on novel agents in renal cell carcinoma.
    Tamaskar I; Pili R
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1817-27. PubMed ID: 19954293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there a role for presurgical therapy for renal cell carcinoma?
    Calabrò F; Sternberg CN
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):807-12. PubMed ID: 20553206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
    Kirkali Z
    BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.